From Genomes and Stem Cells To Fighting Aging

 Aging  

Craig Venter, Peter Diamandis and Robert Hariri have teamed up to form a new company to fight aging. Human Longevity Inc. announced plans to sequence 40,000 human genomes in year to better understand age-related diseases like cancer and dementia.

Craig Venter, is now on a quest to conquor age-related disease.  The well-known scientist behind the successful completion of the Human Genome Project and the team leader of a project to create a custom-made lifeform has started a new venture, Human Longevity Inc.

Venter has teamed up with stem cell pioneer Dr. Robert Hariri and X Prize Foundation founder Dr. Peter Diamandis to form the company. Human Longevity Inc will use both genomics and stem cell therapies to find treatments that allow aging adults to stay healthy and functional for as long as possible.

"I haven't been a skeptic, but I have been one of the people complaining that too little has happened after the human genome was sequenced," Venter told National Geographic.

"We're hoping to make numerous new discoveries in preventive medicine. We think this will have a huge impact on changing the cost of medicine," Venter said on a conference call announcing his latest venture.

Fighting aging is increasingly becoming a scientific and business rallying point; Venter's transition into longevity follows the formation in September of Google-backed biotechnology company Calico.

Robert Hariri, J. Craig Venter, and Peter Diamandis (right to left)
Image Source -Brett Shipe/Science

The company, which will be based in San Diego-based already has $70 million in private backing and has already purchased two ultrafast HiSeq X Ten gene sequencing systems from Illumina Inc, a leading manufacturer of DNA sequencing machines, with the option to buy three more.

Related articles Discovery Of Sirtuin Interactions May Open Up Molecular Fountain Of Youth  Research Into Engineering Genomes Advances  What Does The Exponential Growth Of Genomics Data Actually Mean?

The company plans to use that technology to map 40,000 human genomes in a push to build the world's largest database of human genetic variation. The database will include sequences from the very young through the very old, both diseased and healthy. 40,000 is the calculated number the two gene sequencing machines can complete in a year.

"This will be one of the largest data studies in the history of science and medicine," Venter told the conference call.

Along with gathering whole genome data, the company will collect genetic data on the trillions of microbes - including bacteria, viruses and fungi - living in and on humans.

By better understanding the microbiomes in the gut, in the mouth, on the skin and other sites on the body, the company said it hopes to develop better probiotics as well as better diagnostics and drugs to improve health and wellness.

The company's initial treatment targets will be some of the toughest age-related diseases: cancer, diabetes and obesity, heart and liver diseases, and dementia.

Venter said the company will start first with cancer. It has teamed up with the Moores Cancer Center at the University of California, San Diego, with the goal of sequencing the genomes of everyone who comes there for treatment, as well as doing a full genome sequence on their tumors.

"Cancer is one of the most actionable areas right now with genomic-based therapies," Venter said, adding that cancer is "just the first of a multitude of diseases we will be sequencing this year."

"Undoubtedly, important biologic discoveries will be made along the way, but it remains unclear whether such efforts like Human Longevity Inc and Calico can influence longevity," Dr. Eric Topol, Scripps Health chief academic officer and director of the Scripps Translational Science Institute said.

In addition to UCSD, the company has established strategic collaborations with privately held Metabolon Inc of North Carolina, a company that focuses on biochemical profiling, as well as his own J. Craig Venter Institute, a nonprofit genomics research institute.



SOURCE  Reuters

By 33rd Square

Subscribe to 33rd Square